Johnson & Johnson has officially raised its financial projections for the full year 2026, demonstrating remarkable resilience in the face…
Read More
Johnson & Johnson’s Spravato Remission Data Takes Center Stage in Push for Treatment-Resistant Depression Growth
A recent poster presentation at Psych Congress Elevate by Johnson & Johnson has placed esketamine nasal spray, marketed as Spravato,…
Read More
Johnson & Johnson Forecasts Accelerated Growth in 2026 Driven by New Psoriasis Treatment, Icotyde, and Robust Pharma Portfolio
Johnson & Johnson (J&J) has reported a strong start to 2026, exceeding analyst expectations with robust first-quarter earnings and revising…
Read More
Johnson & Johnson’s Icotyde Poised to Challenge AbbVie’s Skyrizi in Plaque Psoriasis Market
The landscape of plaque psoriasis treatment is on the cusp of a significant shift with the U.S. Food and Drug…
Read More
